在帕廷顿综合征中管理 dystonia
Emilie Pichon1, Aurea Alioth2, Sabina Catalano Chiuvé2
1Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Movement disorders clinical practice
|September 30, 2025
概括
帕廷顿综合征的治疗仍然具有挑战性,手 dystonia 的选择有限. 目前的研究表明,利沃多巴 (l-多巴) 和巴克洛芬有轻微益处,但进一步的研究对于有效的患者管理至关重要.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 运动障碍 运动障碍
背景情况:
- 帕廷顿综合征的特征是双边焦点手 dystonia,智力障碍和口腔运动障碍.
- 与Aristaless相关的家庭盒 (ARX) 基因与帕廷顿综合征有关.
- 帕廷顿综合征中焦点 dystonia 的有效治疗方法尚未确立,导致管理不确定性.
研究的目的:
- 调查帕廷顿综合征中焦点手 dystonia 的治疗选择.
- 评估各种药理和非药理干预措施的疗效.
主要方法:
- 介绍帕廷顿综合征的两个临床病例与ARX基因突变.
- 管理多种药物试验,包括levodopa (l-dopa),trihexyphenidyl,tetrabenazine和类药物.
- 使用肉毒毒素和盲目 dystonia 协议来评估 l-dopa 在一个患者的疗效.
- 对现有治疗研究的系统文献审查.
主要成果:
- 利沃多巴 (l-dopa) 在一个盲目治疗方案下,在一个病人身上只显示了轻微的益处.
- 文献综述表明,使用l-dopa和巴克洛芬可能有轻微的改善.
- 在之前的研究中,propranolol,gabapentin和haloperidol被报告为无效.
- 现有的文献提供了不准确的描述和轻度改进数据,阻碍了最终的结论.
结论:
- 与帕廷顿综合征相关的 dystonia 治疗选择目前有限且难以捉摸.
- 需要进一步的研究,包括额外的案例研究.
- 对帕廷顿综合征的临床特征进行全面的表征和确定有效的治疗方法至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
913
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
913
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.5K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.5K